Table 2.
Molecular biomarkers as therapeutic targets for CTCL.
| Molecular marker/mutation | Targeted therapy | Clinical status | References |
|---|---|---|---|
| CD30 | Brentuximab | Phase II trial | (100) |
| CTLA4 | Ipilimumab | ||
| CD28-CTLA4 fusion | Ipilimumab | (9) | |
| CCR4 | Mogamulizumab | US-FDA approved | (61) |
| TNFRSF1B | Bortezomib | Phase II trial | (5, 6) |
| NFkB | Bortezomib | In-vitro studies, small phase II trials | (6, 101) |
| CD158k/KIR3DL2 | IPH4102 | Phase I trials | NCT02593045 |
| JAK/STAT pathway | Ruxolitinib (JAK1/3) Tofacitinib (JAK1/2) |
In vitro studies | (12) |
| PDCD1 | Pembrolizumab | Phase II trial | NCT02243579) |